会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Extracellular matrix-binding proteins from Staphylococcus aureus
    • 来自金黄色葡萄球菌的细胞外基质结合蛋白
    • US20050026170A1
    • 2005-02-03
    • US10744616
    • 2003-12-24
    • Joseph PattiTimothy FosterElisabet JosefssonDeidre EidhinMagnus HookSamuel Perkins
    • Joseph PattiTimothy FosterElisabet JosefssonDeidre EidhinMagnus HookSamuel Perkins
    • A61K38/00A61K39/00C07K14/31C12Q1/68C07K16/40
    • G01N33/56938A61K38/00A61K39/00C07K14/31G01N2469/00Y10S435/975Y10S530/81Y10S530/825
    • Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD.
    • 描述了分离的细胞外基质结合蛋白,命名为ClfB,SdrC,SdrD和SdrE,以及它们相应的氨基酸和核酸序列和基序。 蛋白质,肽,其片段或其抗原部分可用于预防,抑制,治疗和诊断金黄色葡萄球菌感染以及科学研究工具。 此外,蛋白质,肽,其片段或其抗原部分的抗体或抗体片段也可用于预防,抑制,治疗和诊断金黄色葡萄球菌感染。 特别地,其蛋白质或其抗体可以施用于伤口或用于涂覆生物材料以用作阻断剂以预防或抑制金黄色葡萄球菌与伤口或生物材料的结合。 ClfB是具有约88kDa的预测分子量和约124kDa的表观分子量的细胞壁相关蛋白,其结合可溶性和固定的纤维蛋白原。 ClfB结合纤维蛋白原的α链和β链,并作为聚集因子。 SdrC,SdrD和SdrE是表现出阳离子依赖性配体结合细胞外基质的细胞壁相关蛋白。 已经发现,在SdrC,SdrD,SdrE,ClfA和ClfB的A区域中,存在可用于得到TYTFTDYVD的共有基序的高度保守的氨基酸序列。
    • 2. 发明申请
    • Staphylococcal immunotherapeutics via donor selection and donor stimulation
    • 葡萄球菌免疫治疗通过供体选择和供体刺激
    • US20060222651A1
    • 2006-10-05
    • US11374065
    • 2006-03-14
    • Joseph PattiTimothy FosterMagnus Hook
    • Joseph PattiTimothy FosterMagnus Hook
    • A61K39/40C07K16/12
    • A61K9/0019A61K39/00A61K2039/505C07K16/1271C07K2317/20C07K2317/76
    • A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.
    • 提供了感染或易感染葡萄球菌如金黄色葡萄球菌和表皮葡萄球菌感染的患者的被动免疫的方法和组合物,其包括选择或制备具有高抗体滴度的供体血浆池以精心选择的葡萄球菌 粘附素或MSCRAMM,或其片段或组分,或与其基本上同源的序列。 供体血浆池可以通过将具有高于正常滴度的抗体的单个血液或血液成分样品与一种或多种所选择的粘附素或与细胞外基质蛋白结合的其它蛋白质组合,或通过将精心挑选的蛋白质或肽施用于 诱导所需抗体表达的宿主,随后从被处理的宿主中回收增强的高效价血清或血浆池。